Figure 1.

PIM kinase inhibitor AZD1208 treatment scheme and histological analysis of treated prostate tissue recombinant grafts. A) Scheme for AZD1208 treatment (four trials) of MYC/Pim1-expressing prostate recombination grafts showing the timing and duration of treatment (shaded bars). B) Numbers of mice and individual grafts (number in parentheses) enrolled in the treatment trials. C) Relative change between vehicle-treated and AZD1208-treated tissue recombination graft volumes at harvest. Results are shown as mean ± SD. *Student’s t test P < .05. #Mann-Whitney rank sum test significance at < .05. All statistical tests were two-sided. D) Hematoxylin and eosin (H&E)–stained sections demonstrate more severe lesion (HGPIN) in the vehicle-treated specimens compared with the 30mg/kg AZD1208-treated specimen. Corresponding sections demonstrate yellow fluorescent protein (YFP) immunofluorescence (detected with anti-GFP antibody), indicating the c-MYC/Pim1–transduced cells. E) H&E–stained sections with corresponding YFP by immunohistochemistry (brown) detected with anti-GFP antibody similarly demonstrate worse pathology (HGPIN) in the vehicle-treated specimen compared with the 45mg/kg AZD1208-treated specimen. Scale bars = 0.1mm (short bar), 0.05mm (long bar), respectively, for (D) and (E). H&E = hematoxylin and eosin stain; GFP = green fluorescent protein.